Diagnostics GNA Biosolutions GmbH (SHS IV Fund) Test, test and test again! Diagnostics play a critical role in combating the current coronavirus pandemic (SARS-CoV-2). The quick and comprehensive identification of infected persons is a crucial contribution to the detection and critical disruption of chains of infection. With its ultra-fast PCA (pulse-controlled amplification) technology, GNA, headquartered […]

Diagnostics ndd Medizintechnik AG (SHS IV Fund) Based on what we now know, people with impaired lung function belong to the high-risk group – and not just now, during the current pandemic. Not only do COPD patients (some 50% of whom are unaware of their disease) have impaired or critical lung function, but so do […]

Dr. André Zimmermann, partner at SHS, was a guest in the BVK expert talk. Deputy Managing Director Swantje von Massenbach spoke to him about investments in the health sector, such as medical technology or diagnostics. Among other things, this included a rapid corona test that can achieve a result within 15 minutes with comparable accuracy to tests that still take several hours today. For portfolio companies and SHS investors, what is known as impact investing is particularly important. This means that investments have positive effects on health, the environment or society. You can learn more about this in the video.

With the Investor Network Tyrol, the Tyrolean location agency brings companies and start-ups together with the right investors. In a discussion between Klaus Grössinger from the Investor Network of the Tyrolean location agency and Friedrich Baldinger from the Tübingen-based medical technology and life science investor SHS, they will explain how this works in practice.

“The high demand for digital health offers should not hide the fact that the industry is facing enormous risks,” says Cornelius Maas, SHS Senior Investment Manager, in a guest article in Handelsblatt.

On April 1, 2020, Sascha Alilovic (46) was appointed Managing Partner of SHS Gesellschaft für Beteiligungsmanagement. Whether by way of succession arrangements or growth financing, SHS specializes in investing in innovative healthcare companies with a focus on medical technology and life sciences. Through several funds, SHS has more than EUR 300 million under management. It […]

Neuro Event Labs Oy closes EUR 3.9m Series A investment round from Hadean Ventures, SHS Gesellschaft für Beteiligungsmanagement and Maki.vc Proceeds to support commercial expansion in Europe as well as US market entry Investment round led by Hadean Ventures, joined by SHS Gesellschaft für Beteiligungsmanagement and existing investor Maki.vc Neuro Event Labs Oy today announced […]

While for most companies in Tyrol the corona crisis means the passing of an economic acid test, the Kufstein-based start-up company Single Use Support achieved a significant increase in sales in the first quarter of 2020. The technologies of the biopharmaceutical supplier founded in 2016 are now also being used in the development of a […]

medigroba GmbH, with its headquarters in Balingen, continues to expand and has now also gained a foothold in Hesse following the expansion of the site in North Rhine-Westphalia, where people in need of care have been provided with medical aids since 2019. To support the regional sales team with prompt deliveries, a new location has […]

Amidst the spread of the novel coronavirus COVID-19, the biopharmaceutical industry worldwide is researching for vaccines against the virus. The Tyrolean start-up Single Use Support GmbH is also involved: a biotech company from the USA relies on the technologies of Single Use Support during the clinical phases of vaccine development against SARS-CoV-2 virus. The products […]

c-LEcta, a leading innovator and supplier of biotechnological products for regulated markets like food and pharma, is entering into a development partnership with the MDax-listed company Symrise. Founded in 2003, Symrise AG is one of the world’s leading suppliers of fragrances and flavors.